Picard Medical, Inc. (PMI)
XASE:PMI
Want to see PMI full AI Analyst Report?
PMI Stock Chart & Stats
$1.82
--
Market closed
$1.82
--
Day’s Range― - ―
52-Week Range$0.11 - $13.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.38M
Market Cap
$18.47M
Enterprise Value$300.41M
Total Cash (Recent Filing)$121.00K
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta-2.97
Next Earnings
Sep 21, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding92,349,846
10 Day Avg. Volume2,124,305
30 Day Avg. Volume2,378,935
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap16.26
Enterprise Value/Revenue54.85
Enterprise Value/Gross Profit360.64
Enterprise Value/Ebitda-12.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial TractionSustained top-line momentum, including an 85% YoY Q1 jump and TTM revenue growth, indicates expanding commercial adoption of SynCardia devices and related services. Over 2–6 months this supports scaling revenue, improving operating leverage, and validating go‑to‑market execution if growth persists.
Improving Gross MarginsMaterial margin improvement from negative to mid-teens TTM and 24% in Q1 signals improving unit economics and pricing/mix benefits. If sustained with revenue growth, these margin gains are a durable path to narrowing operating losses and making incremental sales more cash generative.
Market Leadership & PipelineA unique regulatory position and a sizable installed base (>2,100 implants) create durable competitive advantages in advanced heart failure. Progress on the Emperor fully implantable heart (first‑in‑animal trials) offers a clear product roadmap to broaden indications and long‑term addressable market.
Bears Say
Persistent Cash BurnVery large negative operating and free cash flow indicate the business currently destroys cash and will need external financing to sustain operations. Over the medium term this heightens dilution risk, constrains strategic optionality, and places pressure on execution to convert margin gains into positive cash generation.
Negative Equity & Listing RiskA stockholders’ deficit and an active NYSE remediation requirement create structural funding and governance pressure. The need to restore listing standards and shore up equity can force dilutive financings or operational tradeoffs, increasing execution risk and the probability of distracting regulatory remediation efforts.
Very Large Operating & Net LossesExtremely negative operating and net margins show the business has not yet scaled to cover fixed costs. Such deep losses require sustained revenue acceleration and continued margin expansion to reach breakeven, leaving the company vulnerable if commercial gains ebb or R&D/commercial expenses remain elevated.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $0.11 and its highest was $13.68 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Picard Medical, Inc.’s market cap is $18.47M.
When is Picard Medical, Inc.’s upcoming earnings report date?
Picard Medical, Inc.’s upcoming earnings report date is Sep 21, 2026 which is in 89 days.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on May 21, 2026. The company reported -$0.1 earnings per share for the quarter, the consensus estimate of -$0.1 by $0.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 92,349,846 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$0.1 in its last earnings report, expectations of -$0.1. Following the earnings report the stock price went down -8.442%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
PMI Company Deck
PMI Earnings Call
Q4 2026
0:00 / 0:00
PMI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
0.11% Mutual Funds
0.05% Other Institutional Investors
99.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---